

Gates & Cooper LLP

Howard Hughes Center
6701 Center Drive West, Suite 1050
Los Angeles, California 90045

RECEIVED
CENTRAL FAX CENTER

FEB 25 2004

OFFICIAL

FAX TRANSMISSION TO USPTO

TO: Commissioner for Patents
Attn: Examiner Mary Mosher
Patent Examining Corps
Facsimile Center
Alexandria, VA 22313-1450


FROM: Karen S. Canady
OUR REF.: G&C 151.2-US-WO
TELEPHONE: (310) 642-4148

Total pages, including cover letter: 26PTO FAX NUMBER: (703) 872-9306


If you do NOT receive all of the pages, please telephone us at (310) 641-8797, or fax us at (310) 641-8798.

Title of Document Transmitted:	RCE, AMENDMENT UNDER 37 C.F.R. §1.111 INCLUDING EXHIBITS A AND B, AND AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT IN THE AMOUNT OF \$385 FOR FILING FEE
Applicant:	Ulrich Schubert et al.
Serial No.:	09/913,927
Filed:	January 14, 2002
Group Art Unit:	1648
Our Ref. No.:	G&C 151.2-US-WO

Please charge all fees to Deposit Account No. 50-0494 of Gates & Cooper LLP.

By: 
 Name: Karen S. Canady
 Reg. No.: 39,927

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.


Signature
Date

KSC/sjm


G&C 151.2-US-WO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ulrich Schubert et al. Examiner: Mary Mosher
 Serial No.: 09/913,927 Group Art Unit: 1648
 Filed: January 14, 2002 Docket: G&C 151.2-US-WO
 Title: SYNTHETIC PEPTIDE OF REGULATORY VIRUS PROTEIN R (VPR) OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) AND THE UTILIZATION THEREOF

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being filed via facsimile transmission to the U.S. Patent and Trademark Office on February 25, 2004.

By 
 Name: Karen S. Canady

REQUEST FOR CONTINUED EXAMINATION (RCE) UNDER 37 C.F.R. §1.114

MAIL STOP RCE
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

This is a Request for Continued Examination (RCE) under 37 CFR § 1.114 of patent application Serial No. 09/913,927, filed on January 14, 2002, and entitled SYNTHETIC PEPTIDE OF REGULATORY VIRUS PROTEIN R (VPR) OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) AND THE UTILIZATION THEREOF, in which no payment of the issue fee, abandonment of, or termination of proceedings has occurred.

- An Amendment Under 37 C.F.R. §1.111 including Exhibits A and B is attached.
- Pursuant to a telephone discussion today between Applicants' undersigned attorney and Examiner Mosher, an Advisory Action will be filed today and no fee is due for submission of a response on this date.
- The fee has been calculated as shown below in the "Claims as Filed" table.

CLAIMS PRESENT

Claims Remaining:	Highest Number Previously Paid For:	Number Extra	Rate		Fee
Basic Filing Fee					\$385.00
Total Claims					
12	20	0	x \$9.00	=	\$0.00
Independent Claims					
1	3	0	x \$43.00	=	\$0.00
MULTIPLE DEPENDENT CLAIM FEE					\$0.00
TOTAL FILING FEE					\$385.00

- A charge to the Deposit Account identified below in the amount of \$385.00 to cover the RCE Filing Fees.
- Address all future communications to the Attention of Karen S. Canady at Gates & Cooper LLP, Howard Hughes Center, 6701 Center Drive West, Suite 1050, Los Angeles, California 90045, Telephone: (310) 641-8797.

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

Please charge all fees to Deposit Account No. 50-0494 of Gates & Cooper LLP. A duplicate of this paper is enclosed.

(PTO TRANSMITTAL – FILING UNDER 37 CFR §1.114

02-25-2004 03:07PM FROM-Gates & Cooper LLP


+13106418798

T-064 P.003/026 F-139

CUSTOMER NUMBER 22462

GATES & COOPER LLP

Howard Hughes Center
6701 Center Drive West, Suite 1050
Los Angeles, CA 90045
(310) 641-8797

By: 

Name: Karen S. Canady
Reg. No.: 39,927
KSC/sjm

(PTO TRANSMITTAL - FILING UNDER 37 CFR §1.114

PAGE 3/26 * RCVD AT 2/25/2004 5:59:32 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/0 * DNIS:8729307 * CSID:+13106418798 * DURATION (mm:ss):06:54